Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities [20]

British Journal of Dermatology

Volumn 158, Issue 2, 2008, Pages 431-432

  Potouridou, I ^a   Korfitis, C ^a   Ioannidou, D ^a   Polydorou, D ^a   Zakopoulou, N ^a   Stratigos, A J ^a   Katsambas, A D ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Classic Kaposi sarcoma; Comorbidities; Elderly; Pegylated liposomal doxorubicin

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; DOXORUBICIN; VINBLASTINE;

AGE DISTRIBUTION; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FATIGUE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KAPOSI SARCOMA; LETTER; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; REMISSION; TEMPORAL ARTERITIS; TREATMENT DURATION; TREATMENT OUTCOME; VESICULAR RASH;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; MALE; POLYETHYLENE GLYCOLS; SARCOMA, KAPOSI; SKIN NEOPLASMS;

EID: 38349091070     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08345.x     Document Type: Letter

References (6)

1. Bogner JR, Kronawitter U, Rolinski B et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994 7 : 463 8.
2. Mitsuyasu RT, Groopman JE. Biology and therapy of Kaposi's sarcoma. Semin Oncol 1984 11 : 53 9.
3. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989 7 : 1201 7.
4. Costa da Cunha CS, Lebb C, Rybojad M et al. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b. Arch Dermatol 1996 132 : 285 90.
5. Kreuter A, Rasokat H, Klouche M et al. Liposomal pegylated doxorubicin versus low-dose recombinant interferon alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest 2005 23 : 653 9.
6. Young AM, Dhillon T, Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol 2004 5 : 654.